Lung Neoplasms Clinical Trial
— Intense-CTOfficial title:
Does Intense Regimented Surveillance Improve the Rates of Therapeutic Re-Intervention After Lung Cancer Surgery: A Pilot Study for the Intense-CT Trial
| Verified date | December 2018 |
| Source | McMaster University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
After curative lung cancer surgery, there is a risk of recurrence of the primary cancer, or
development of a new cancer. Historically, patients who have undergone curative lung cancer
surgery have been monitored with chest radiographs (CXR). Unfortunately, 70% of such patients
still die of lung cancer. As a result, there has been interest in other methods of
surveillance in order to detect recurring or new cancers earlier and have more success in
treating them. One such technique is Low Dose Computed Tomography (LDCT), which is currently
the standard of care and surveillance at this institution. This pilot study aims to determine
whether regimented, intensive, short interval LDCT surveillance leads to higher rates of
detection and treatment of recurring lung cancers. The study group will be followed up
according to a regimented surveillance program using LDCT. The study group will be compared
to a group of historical controls whose follow up after surgery was not standardized, but
rather left up to the discretion of the individual surgeon. If the results of this study show
improvements in detection and treatment of recurrent cancers, it will allow for a larger
trial to study the effects of the LDCT surveillance program on lung cancer survival.
The study question aims to determine whether for survivors after curative surgery for Stage I
and Stage II lung cancer, a structured Surveillance Program with Low Dose CT can increase the
rate of detection and treatment of recurring or new cancers when compared to historical
non-structured surveillance with CXR. This study will also determine if it is warranted to
pursue a larger scale randomized controlled trial to further investigate optimal LDCT
surveillance follow-up intervals and long-term lung cancer survival.
| Status | Completed |
| Enrollment | 313 |
| Est. completion date | April 30, 2018 |
| Est. primary completion date | April 30, 2018 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: - Patients must be at minimum 18 years of age - Patients must have undergone complete resection for pathological Stage I or Stage II lung cancer - Patients must demonstrate the ability to understand English - Patients must be able to demonstrate aptitude and willingness to comply with describes study procedures Exclusion Criteria: - Patients with residual gross or microscopic disease after surgery - Patients with pathological Stage III or Stage IV lung cancer |
| Country | Name | City | State |
|---|---|---|---|
| Canada | St. Joseph's Healthcare Hamilton | Hamilton | Ontario |
| Lead Sponsor | Collaborator |
|---|---|
| McMaster University | McMaster Surgical Associates |
Canada,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Rate of therapeutic re-intervention within the first year after curative resection of lung cancer | Defined by: 1) rate of curative intent radiation treatment after detection of recurrent or new primary lung cancer 2) rate of curative intent reoperation after detection of recurrent or new primary lung cancer. Measured by frequency of events. | One year after surgery | |
| Secondary | Rate of adherence to follow-up visits | Measured by frequency of events | One year after surgery | |
| Secondary | Morbidity of associated interventions | Measured by frequency of events | One year after surgery |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
| Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
| Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
| Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
| Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
| Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
| Completed |
NCT02106143 -
RejuvenAirâ„¢ System Lobectomy Safety and Histology Study
|
N/A | |
| Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
| Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
| Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
| Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|